To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Kedem Pharmaceuticals Signs Contract with Corealis Pharma
Kedem Pharmaceuticals Inc. has announced that it has signed a contract with a GMP pharmaceutical FDA compliant formulation development company, Corealis Pharma, Inc. for the production of the phase I clinical supplies of KDM-1102, the Company’s second lead therapeutic drug.
The KDM-1102 drug is a new sublingual formulation of propanolol. The formulation development of the KDM-1102 drug is now completed and can be produce in large volume.
“We are pleased with the progress we have been making in our development program on KDM-1102, our Second lead therapeutic drug for cardiovascular and anxiety attacks”, said Dr. Hassan Salari, Kedem Pharmaceuticals, President & CEO.
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
